These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35377160)

  • 21. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
    Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.
    Mosca L; Navar AM; Wenger NK
    J Womens Health (Larchmt); 2020 Aug; 29(8):1091-1100. PubMed ID: 32297837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
    Gaba P; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Giugliano RP; Martens FMAC; Gibson CM; Ballantyne CM;
    J Am Coll Cardiol; 2022 May; 79(17):1660-1671. PubMed ID: 35483753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
    Szarek M; Bhatt DL; Miller M; Brinton EA; Jacobson TA; Tardif JC; Ballantyne CM; Mason RP; Ketchum SB; Lira Pineda A; Doyle RT; Steg PG;
    J Am Coll Cardiol; 2024 Apr; 83(16):1529-1539. PubMed ID: 38530686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn.
    Miller M; Bhatt DL; Brinton EA; Jacobson TA; Steg PG; Pineda AL; Ketchum SB; Doyle RT; Tardif JC; Ballantyne CM
    Eur Heart J Open; 2023 Nov; 3(6):oead114. PubMed ID: 38035037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date.
    Jia X; Koh S; Al Rifai M; Blumenthal RS; Virani SS
    Vasc Health Risk Manag; 2020; 16():1-10. PubMed ID: 32021223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
    Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR
    Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
    Miller M; Ballantyne CM; Bays HE; Granowitz C; Doyle RT; Juliano RA; Philip S
    Am J Cardiol; 2019 Sep; 124(5):696-701. PubMed ID: 31277790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction.
    Huston J; Schaffner H; Cox A; Sperry A; Mcgee S; Lor P; Langley L; Skrable B; Ashchi M; Bisharat M; Gore A; Jones T; Sutton D; Sheikh-Ali M; Berner J; Goldfaden R
    Am J Cardiovasc Drugs; 2023 Jul; 23(4):393-406. PubMed ID: 37188993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
    Gaba P; Bhatt DL; Giugliano RP; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Ballantyne CM; Pinto DS; Budoff MJ; Gibson CM
    J Am Coll Cardiol; 2021 Oct; 78(15):1525-1537. PubMed ID: 34620410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Braeckman RA; Philip S; Stirtan WG; Doyle RT; Soni PN; Juliano RA
    J Clin Lipidol; 2016; 10(3):635-645.e1. PubMed ID: 27206952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
    Budoff MJ; Muhlestein JB; Bhatt DL; Le Pa VT; May HT; Shaikh K; Shekar C; Kinninger A; Lakshmanan S; Roy SK; Tayek J; Nelson JR
    Cardiovasc Res; 2021 Mar; 117(4):1070-1077. PubMed ID: 32609331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular risk reduction with icosapent ethyl.
    Patel PN; Patel SM; Bhatt DL
    Curr Opin Cardiol; 2019 Nov; 34(6):721-727. PubMed ID: 31464773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Icosapent ethyl for treatment of elevated triglyceride levels.
    Nelson SD; Munger MA
    Ann Pharmacother; 2013 Nov; 47(11):1517-23. PubMed ID: 24259598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides.
    Pareek M; Mason RP; Bhatt DL
    Expert Opin Drug Saf; 2022 Jan; 21(1):31-42. PubMed ID: 34253137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?
    Ferrières J; Bataille V; Puymirat E; Schiele F; Simon T; Danchin N;
    Clin Cardiol; 2020 Nov; 43(11):1260-1265. PubMed ID: 32720384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
    Branch KR; Probstfield JL; Eikelboom JW; Bosch J; Maggioni AP; Cheng RK; Bhatt DL; Avezum A; Fox KAA; Connolly SJ; Shestakovska O; Yusuf S
    Circulation; 2019 Aug; 140(7):529-537. PubMed ID: 31163978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES]).
    Wong ND; Fan W; Philip S; Granowitz C; Toth PP
    Am J Cardiol; 2020 Nov; 134():62-68. PubMed ID: 32933754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
    Budoff MJ; Bhatt DL; Kinninger A; Lakshmanan S; Muhlestein JB; Le VT; May HT; Shaikh K; Shekar C; Roy SK; Tayek J; Nelson JR
    Eur Heart J; 2020 Oct; 41(40):3925-3932. PubMed ID: 32860032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.